15-year follow-up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation

Transplantation

Volumn 98, Issue 1, 2014, Pages 47-53

  Roodnat, Joke I ^a   Hilbrands, Luuk B ^b   Hené, Ronald J ^e   De Sévaux, Ruud G L ^b   Smak Gregoor, Peter J H ^c   Kal Van Gestel, Judith A ^a   Konijn, Cynthia ^d   Van Zuilen, Arjan ^e   Van Gelder, Teun ^a   Hoitsma, Andries J ^b   Weimar, Willem ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^d Dutch Transplant Foundation   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

calcineurin inhibitor withdrawal; cardiovascular disease; graft survival; long term; malignancy; randomized trial; Renal transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ACUTE GRAFT REJECTION; ADULT; AGE; ARTICLE; CAUSE OF DEATH; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIGESTIVE SYSTEM PERFORATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GRAFT FAILURE; GRAFT SURVIVAL; HEPATORENAL SYNDROME; HUMAN; INCIDENCE; INFECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOUTH ULCER; MULTICENTER STUDY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SICKLE CELL CRISIS; SURVIVAL RATE; TRAFFIC ACCIDENT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VASCULAR DISEASE;

ADULT; BIOLOGICAL MARKERS; CALCINEURIN; CREATININE; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOPHENOLIC ACID; NETHERLANDS; PREDNISONE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84903769271     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000442774.46133.71     Document Type: Article

References (30)

1. European Multicentre Trial Group. Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet 1983; 2: 986.
2. European Mycophenolate Mofetil Cooperative Study Group. Placebocontrolled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321.
3. Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2010 Data Report. Am J Transplant 2012; 12s1: 1.
4. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876.
5. Ekberg H, Tedesco-Silva H, Demirbas A, et al. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
6. Weir MR, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int 2011; 79: 897.
7. Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910.
8. Smak Gregoor PJ, de Se'vaux RG, Ligtenberg G, et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13: 1365.
9. Abramowicz D, Del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16: 2234.
10. Oberbauer R, Segoloni G, Campistol JM, et al., RapamuneMaintenance Regimen Study Group. Early cyclosporine withdrawal from a sirolimusbased regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18: 22.
11. Lebranchu Y, Thierry A, Thervet E, et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the postconcept study. Am J Transplant 2011; 11: 1665.
12. Gallagher MP, Hall B, Craig J, et al. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004; 78: 1653.
13. Joss N, Rodger RS,McMillan MA, et al. Randomized study comparing cyclosporine with azathioprine one year after renal transplantation- 15-year outcome data. Transplantation 2007; 83: 582.
14. Bakker RC, Hollander AA, Mallat MJ, et al. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int 2003; 64: 1027.
15. Gallagher M, Jardine M, Perkovic V, et al. Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation 2009; 87: 1877.
16. Opelz G, Dohler B. Effect on kidney graft survival of reducing or discontinuing a maintenance immunosuppression after the first year post transplant. Transplantation 2008; 86: 371.
17. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55: 993.
18. Joseph JT, Kingsmore DB, Junor BJ, et al. The impact of late acute rejection after cadaveric kidney transplantation. Clin Transplant 2001; 15: 221.
19. Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 2011; 6: 430.
20. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12: 210.
21. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261.
22. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokineticpharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002; 3: 759.
23. Kiberd BA, Lawen J, Fraser AD, et al. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 2004; 7: 1079.
24. van Gelder T, Tedesco Silva H, de Fijter JW, et al. Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. Transplantation 2010; 89: 595.
25. Gregoor PJ, de Se'vaux RG, Hené RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999; 68: 1603.
26. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119.
27. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression. BMJ 2005; 331: 810.
28. Gallagher MP, Kelly PJ, Jardine M, et al. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol 2010; 5: 852.
29. van de Wetering J, Roodnat JI, Hemke AC, et al. Patient survival after the diagnosis of cancer in renal transplant recipients: a nested casecontrol study. Transplantation 2010; 90: 1542.
30. Salvadori M, Bertoni E. Is it time to give up with calcineurin inhibitors in kidney transplantation? World J Transplant 2013; 3: 7.